$GTBP
GT Biopharma, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · San Francisco, CA
GTBP chart
What traders are saying about $GTBP
Latest postsGT Biopharma, Inc. news
- Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market
The Manila Times ·
- GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting
Yahoo Finance ·
- A study on making pancreatic cancer more vulnerable to immune treatment gets an oral slot
Stock Titan ·
- GT Biopharma, Inc. Estimates – NASDAQ:GTBP
TradingView ·
- EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy
Yahoo Finance ·
- GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma
Yahoo Finance ·
- GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026
Yahoo Finance ·
- GT Biopharma Reports Second Quarter 2026 Financial Results
Yahoo Finance ·
- GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
Yahoo Finance ·
- EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout
Yahoo Finance ·
- GT Biopharma Reports First Quarter 2026 Financial Results
Yahoo Finance ·
- GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
Yahoo Finance ·
GT Biopharma, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Net income | -$28.4M | -$13.2M | -$7.6M | -$20.9M |
| Diluted EPS | $-6.68 | $-6.94 | $-5.64 | $-19.66 |
| Total assets (year end) | $8.1M | $4.2M | $14.1M | $16.7M |
| Cash and equivalents (year end) | $6.8M | $4.0M | $1.1M | $5.7M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About GT Biopharma, Inc.
- Ticker
- GTBP (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- San Francisco, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 109657
- Former names
- GT Biopharma, Inc., OXIS INTERNATIONAL INC
Frequently asked questions
What exchange is GT Biopharma, Inc. listed on?
GT Biopharma, Inc. trades on the Nasdaq under the ticker symbol GTBP.
What industry is GT Biopharma, Inc. in?
GT Biopharma, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is GT Biopharma, Inc. headquartered?
GT Biopharma, Inc.'s business address on file with the SEC is in San Francisco, CA.
When does GT Biopharma, Inc.'s fiscal year end?
GT Biopharma, Inc.'s fiscal year ends on December 31.
How much revenue did GT Biopharma, Inc. report?
GT Biopharma, Inc. reported $0 in revenue for calendar year 2020, according to its SEC filings.